4-(6-氯-2-三氟甲基嘧啶-4-基)吗啉 | 1189444-94-7

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 4-(6-氯-2-三氟甲基嘧啶-4-基)吗啉
• 英文名称: 4-(6-Chloro-2-trifluoromethylpyrimidin-4-yl)morpholine
• 英文别名: 4-[6-chloro-2-(trifluoromethyl)pyrimidin-4-yl]morpholine
• CAS: 1189444-94-7
• 化学式: C₉H₉ClF₃N₃O
• 分子量: 267.63
• InChiKey: CBYBNUMRYGBXOS-UHFFFAOYSA-N

物化性质

• 沸点：
  304.7±42.0 °C(Predicted)
• 密度：
  1.449±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  38.2
• 氢给体数：
  0
• 氢受体数：
  7

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

文献信息

• Non-systemic TGR5 agonists
  申请人：Venenum Biodesign, LLC

  公开号：US10654834B2

  公开（公告）日：2020-05-19

  The present invention relates to tricyclic compounds of formula (I) and formula (II), or a pharmaceutically acceptable salt thereof. The present tricyclic compounds are useful non-systemic TGR5 agonists that can be used to treat diabetic diseases in human. The present invention provides a pharmaceutical composition containing tricyclic compounds of formula (I) and formula (II) and a method of making as well as a method of using same in treating patients inflicted with metabolic disorders by administering same. The compounds of the present invention may be used in combination with additional anti-diabetic drugs.

  本发明涉及式（I）和式（II）的三环化合物或其药学上可接受的盐。本发明的三环化合物是有用的非系统性 TGR5 激动剂，可用于治疗人类糖尿病疾病。本发明提供了一种含有式（I）和式（II）三环化合物的药物组合物及其制造方法，以及一种通过给药治疗代谢紊乱患者的方法。本发明的化合物可与其他抗糖尿病药物联合使用。
• NOVEL NON-SYSTEMIC TGR5 AGONISTS
  申请人：Venenum Biodesign, LLC

  公开号：US20190330191A1

  公开（公告）日：2019-10-31

  The present invention relates to tricyclic compounds of formula (I) and formula (II), or a pharmaceutically acceptable salt thereof. The present tricyclic compounds are useful non-systemic TGR5 agonists that can be used to treat diabetic diseases in human. The present invention provides a pharmaceutical composition containing tricyclic compounds of formula (I) and formula (II) and a method of making as well as a method of using same in treating patients inflicted with metabolic disorders by administering same. The compounds of the present invention may be used in combination with additional anti-diabetic drugs.